[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586348":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":34,"locations":40,"responsibleParty":53,"collaborators":56,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":33,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":33,"enrollmentInfo":74,"targetDuration":33,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":86,"whyStopped":33,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Esketamine group","EXPERIMENTAL","Esketamine+ PRF group",[13],"Drug: esketamine group",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","ACTIVE_COMPARATOR","PRF group",[19],"Drug: PRF group",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","esketamine group","in addition to receiving the combination of PRF of DRG and standardized drug treatment, patients will also undergo a single intravenous infusion of esketamine.",[9],[27],"esketamine+PRF+ standardized drug treatment",{"type":22,"name":17,"description":29,"armGroupLabels":30,"otherNames":31},"In the control group, patients will receive PRF+standardized drug treatment. Pulsed radiofrequency (PRF) will be performed on DRG by an designated physician in each participating center. They will be treated with PRF (PMG-230, Baylis Medical Inc.) using a 21-gauge sterilized radiofrequency needle (a 10-cm trocar with a 5-mm active tip, PMF-21-100-5, Baylis Medical Inc.), which are carefully inserted until the needle tip reaches the upper edge of the intervertebral foramen. The parameters of PRF treatment will be set at 42 ℃, 2 Hz with 20 milliseconds current. The standardized drug treatment will include antiviral therapy, anticonvulsant treatment, three-step analgesic therapy",[15],[32],"PRF+standardized drug treatment",null,[35],{"name":36,"role":37,"phone":38,"phoneExt":33,"email":39},"Fang Luo","CONTACT","+86 13611326978","13611326978@163.com",[41],{"facility":5,"status":33,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":33},"Beijing","Beijing Municipality","100070","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},{"type":54,"investigatorFullName":36,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Director of Department of Day surgery and Pain Management",[57,59,61,63],{"name":58,"class":6},"Beijing Xiaotangshan Hospital",{"name":60,"class":6},"The First Hospital of Fangshan District,Beijing",{"name":62,"class":6},"Beijing Ditan Hospital",{"name":64,"class":6},"Hengshui People's Hospital","100586348","esketamine-combined-with-prf-of-drg-for-acutesubacute-zoster-associated-pain-100586348",false,"NCT06914206","Esketamine Combined With PRF of DRG for Acute\u002FSubacute Zoster-associated Pain","Esketamine Intravenous Infusion Combined With Pulsed Radiofrequency of Dorsal Root Ganglion for Acute and Subacute Herpes Zoster Neuralgia: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Ages more than 18 years;\n2. Patients with onset of herpes zoster (HZ) rash less than 90 days;\n3. HZ affected the spinal nerves (cervical\u002Fthoracic\u002Flumbar nerve);\n4. Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)；\n5. Planned to perform CT-guided PRF treatment of the dorsal root ganglion(DRG).\n\nExclusion Criteria:\n\n1. Obstructive sleep apnoea syndrome;\n2. Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.\n3. A history of systemic immune diseases, organ transplantation, or cancers;\n4. A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;\n5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;\n6. Comorbid hyperthyroidism or phaeochromocytoma;\n7. Recent history of drug abuse;\n8. Having contraindications to esketamine;\n9. Communication difficulties.\n10. Women who are preparing for pregnancy, in the pregnancy or lactation period.","ALL","18 Years",{"count":75,"type":76},184,"ESTIMATED","INTERVENTIONAL",[79],"NA","To assess the 1-month effects and safety of esketamine - PRF -standardized drug treatment against PRF -standardized drug treatment acute\u002Fsubacute zoster-associated pain (ZAP) patients.",[82],"Herpes Zoster",[84,85],"Herpes Zoster Neuralgia","Esketamine","NOT_YET_RECRUITING","2025-04-05",{"date":89,"type":90},"2025-04-09","ACTUAL",{"date":92,"type":76},"2025-04-01",{"date":94,"type":76},"2026-07-01",{"name":5,"class":6},1]